Swedish Orphan Biovitrum (STO: SOBI) today reported a complete consent to gain USA-based Dova Pharmaceuticals (Nasdaq: DOVA) by methods for a delicate offer. The thought comprises of a forthright installment of $27.50 per share in real money and, one non-tradeable Contingent Value Right (CVR). The CVR qualifies Dova investors for an extra $1.50 per share […]
